Here we show in a cohort of neurological patients that the CSF levels of the major proteolytic fragment of the perineuronal ECM proteoglycan neurocan, neurocan-C, are significantly higher in the ALS group as compared to controls, but also to epilepsy and CSVD patients. Here, NCAN is linked to epilepsy.